BIIB Related Earnings News
-
Biogen's (BIIB) BG-12 Data Not Inflated
-
Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
-
Biogen's (BIIB) TECFIDERA Scripts Accelerating WoW
-
Scripts Data Indicates Biogen's (BIIB) Tecfidera Could Beat 2013 Estimates by $400M
-
Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List
-
Goldman Sachs Upgrades Amgen (AMGN) to Conviction Buy
-
Deutsche Bank Sees Upside for Biogen's (BIIB) Tecfidera
-
Jefferies Lifts Numbers on Biogen (BIIB) Post Q1
-
Deutsche Bank Maintains Buy on Biogen (BIIB)
-
Biogen Idec, Inc. (BIIB) Tops Q1 EPS by 34c; Boosts FY13 Outlook
-
Deutsche Bank Raises Biogen (BIIB) Price Target to $240
-
Strong Biogen (BIIB) Tecfideara Sales Tied to Patient 'Warehousing'
-
Early Data Says Biogen's (BIIB) Tecfidera Doing Well - Analyst
-
Biogen (BIIB) Target Raised to $215 at Jefferies after Tecfidera Approved with Favorable Label
-
What Next for Biogen (BIIB)? Anlaysts Weigh In
-
Biogen Idec, Inc. (BIIB) Misses Q4 EPS by 6c; Guides FY13 EPS Below Views
-
Biogen Idec, Inc. (BIIB) Tops Q3 EPS by 32c
-
UPDATE: UBS Downgrades Biogen (BIIB) to Neutral; Risk/Reward Now Balanced
-
UBS Maintains a 'Buy' on Biogen (BIIB); Key Takeaways from 2Q12
-
Jefferies Maintains a 'Buy' on Biogen (BIIB) on Strong Q2; Adjusting Numbers
-
Biogen Idec, Inc. (BIIB) Reports Solid Q2 Results
-
Q2 Kickoff: Alcoa (AA) Investors to Focus on LME Prices, Downstream Ops, and China
-
UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk
-
Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus
-
Biogen (BIIB) Guides FY12; Sees Buying Back an Added $500M in Stock
-
Biogen Idec, Inc. (BIIB) Misses Q1 EPS by 8c; Guides FY12
-
Baird Maintains a 'Neutral' on Biogen (NASDAQ: BIIB); Raising Estimates Ahead of Earnings
-
TYSABRI Lifts Biogen (BIIB) to Q4 Beat; FY12 Outlook is Muted
-
Biogen Idec, Inc. (BIIB) Tops Q4 EPS by 2c; Guides FY12 EPS Below View
-
Biogen Idec (BIIB) Updates on Four Growth Strategies for FY12
-
Biogen Idec, Inc. (BIIB) Tops Q3 Adj-EPS by 8c
-
Biogen Idec, Inc. (BIIB) Misses Q2 EPS by 1c, Sales Beat; Guides FY11
-
Biogen Idec (BIIB) Tops Q1 EPS by 2c
-
Biogen (BIIB) Posted Strong Q4 Results; Guides FY11 EPS Ahead of Street
-
Biogen Idec (BIIB) Posts Q4 EPS of $1.42; Guides FY11
-
Biogen Idec (BIIB) Announces Organizational and Streategic Changes; Will Reduce Workforce by 13%; Increases FY10 EPS Outlook
-
Biogen (BIIB) Tops Q3 Earnings Views
-
Biogen (BIIB) Reports Q2 EPS of $1.31; Raises FY10 EPS Outlook
-
Biogen Idec (BIIB) Misses Q1 EPS by 5c
-
Biogen Idec (BIIB) Reports Solid Q4 Profits and Provides Better-than-Expected Outlook
-
Biogen (BIIB) Reports Q4 Adj-EPS of $1.20, Beats by 15c; Guides FY10 Above the Street
-
Biogen (BIIB) Tops Q3 Views; Announces $1B Buyback; Guides FY09
-
Highlights From Biogen Idec's (BIIB) Q2 Conference Call: Guides In-line for FY
-
Biogen Idec (BIIB) Tops Q2 Views; Guides FY09
-
Biogen (BIIB) Reports Q1 EPS of $1.05, Beats by 4c
-
Biogen (BIIB) to Provide Updates on R&D Pipeline
-
Biogen Idec (BIIB) Reports In-Line Q4; Guides
-
Biogen (BIIB) Tops Q3 Views; Guides FY08
-
Biogen (BIIB) Tops Q2 View; Guides FY08
-
Biogen Idec (BIIB) Details Outlook Through 2010
Back to BIIB Stock Lookup
